Report Highlights

U.S. Role in the Global Compression Therapy Supply Chain

The United States is the largest consumer of compression therapy products globally, yet it is a net importer across most product lines. Domestic output centers on intermittent pneumatic compression devices and specialty garments produced in North Carolina, Ohio, and New Jersey, while elastic knit hosiery and yarn largely arrive from China, Thailand, and Mexico. Customs import data show medical compression hosiery entering through Los Angeles and Long Beach ports dominate inbound volumes, shaping the national logistics footprint.

Export volumes are modest, with outbound shipments concentrated in Canada, the United Kingdom, and Germany, primarily for finished medical garments and refurbished pneumatic units. Value-add sits in device engineering, FDA-cleared controller software, and clinical distribution, not in raw textile production. Vulnerability is structural: a single Asian yarn disruption delays hospital restocking within weeks, because domestic knitting capacity covers only a small fraction of national hosiery demand.

Growth Drivers for U.S. Compression Therapy Trade and Production

Three forces are expanding domestic production and import flows. First, the aging population, with Americans aged 65 and older exceeding 61 million, is widening venous insufficiency and lymphedema caseloads. Second, hospital-at-home programs are shifting device purchasing toward durable medical equipment suppliers in Texas, Florida, and Arizona, increasing demand for portable pneumatic units, which carry unit values roughly three times those of legacy stockings.

Third, the Medicare DMEPOS coverage framework and expanded lymphedema benefits are sustaining reimbursed volume for sleeve and garment products. Import substitution is emerging in Mexico, where maquiladora knitting plants in Ciudad Juárez and Tijuana are qualifying for USMCA-compliant origin status. That shift reduces tariff exposure on Asian yarns and shortens replenishment cycles for U.S. distributors serving hospital systems in the Southwest. Fabric innovation also favors domestic blends engineered for pressure accuracy.

Supply Chain Risks and Trade Barriers

Raw material dependency is the dominant risk. Spandex and nylon yarns used in graduated compression knits are sourced largely from Asian producers, and Section 301 duties on Chinese textile inputs have raised landed costs for garment manufacturers. Additional tariff rounds announced in 2025 added exposure on Thai and Vietnamese yarn shipments, compressing margins for mid-tier distributors that lack inventory buffers. Pumps and microcontrollers in pneumatic devices carry similar Asian sourcing exposure.

Logistics and regulatory friction add a second layer. Port congestion at Los Angeles and Long Beach has extended container dwell times, while FDA 510(k) clearance requirements for pneumatic compression devices lengthen time to market for design changes. Currency movements matter less for domestic buyers, but Canadian and Mexican suppliers invoicing in USD face peso and loonie swings that compress contract pricing. Reimbursement lag under DME competitive bidding also delays cash recovery for smaller suppliers.

Trade and Investment Opportunities in the United States

Import substitution offers the clearest commercial opening. Domestic contract manufacturers in North Carolina and South Carolina that hold ISO 13485 certification can capture hospital private-label garment programs now sourced offshore. Investors should target pneumatic device assembly in Texas, where proximity to Mexican component suppliers and existing medical manufacturing clusters lowers landed cost per unit. Capacity additions should be commissioned before the next USMCA review window closes.

New export markets exist in the Gulf Cooperation Council and Japan, where aging demographics and reimbursement expansion mirror U.S. trends. Logistics hub development at Memphis and Dallas-Fort Worth offers cross-dock consolidation for pneumatic device components and finished garments. Inbound FDI from European hosiery groups, including Sigvaris and Medi, is accelerating U.S. finishing and fitting-center investment. Fitting-center networks also raise sell-through for prescription garments.

Market at a Glance

Leading Market Participants

• Tactile Medical
• Medtronic
• Essity
• Sigvaris
• Medi
• Juzo
• Getinge
• Bio Compression Systems
• Medline Industries
• Carolon

Regulatory and Trade Policy Environment

Medical compression hosiery entering the United States falls under HTSUS 6115.10, and pneumatic compression devices fall under HTSUS 9019.10. Section 301 duties apply to Chinese-origin goods, while USMCA preference is available for qualifying Mexican and Canadian content. FDA regulates pneumatic compression devices under 21 CFR 890.5800 through 510(k) clearance, and the Quality Management System Regulation aligned with ISO 13485 takes full effect in February 2026.

Reimbursement policy sets commercial terms. CMS lists compression garments under HCPCS L-codes and pneumatic devices under E0650 and E0676 within DMEPOS, with competitive bidding shaping supplier eligibility and pricing. Federal Trade Commission scrutiny and state licensing requirements for fitting specialists constrain distributor models. Foreign acquisitions of device manufacturers with defense-adjacent supply face CFIUS review.

U.S. Compression Therapy Supply Chain Outlook to 2032

Nearshoring to Mexico will reshape the knitting base through 2032, with automated flat-knit lines in border states reducing dependence on Asian labor-intensive production. Domestic pneumatic assembly will expand in Texas and the Carolinas as component localization improves. Trade flows will shift from finished garment imports toward semi-finished yarn and component imports from USMCA partners.

Technology will alter comparative advantage. Sensor-enabled compression sleeves and connected pneumatic controllers favor firms with embedded software and remote monitoring capability, rather than firms with textile scale alone. Manufacturers that integrate data platforms with reimbursement documentation will capture share as payers tighten evidence requirements for compression products.